Download our whitepaper,
"Understanding Attention-Deficit/Hyperactivity Disorder (ADHD): Epidemiology, Clinical Implications & Strategies for Clinical Trial Success"

What's Inside:
- Key FDA-Approved Pivotal Endpoints for ADHD Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for ADHD.
- Comprehensive Analysis of FDA-Approved ADHD Drugs.
- How Diagnostic Criteria for ADHD Have Evolved and Impact Research.
- Overcoming Common Pitfalls in ADHD Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
ADHD Clinical Trials
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that are more frequent and severe than typically observed in individuals at a comparable level of development.
The evolving understanding of ADHD has significantly impacted clinical practice and research directions. Clinicians now adopt a more integrated approach in diagnosis and treatment, considering the individual's life context, comorbid conditions, and unique symptom presentation. In research, there is an increasing focus on identifying endophenotypes, exploring non-pharmacological interventions, and understanding the long-term outcomes of those living with ADHD.
Roughly
55%
of children with ADHD continue to experience symptoms into adulthood
ADHD affects around
6%
of children worldwide
ADHD costs the U.S. economy roughly
$77b
each year due to healthcare expenses, work loss, and reduced productivity
Our clinical team has over
120
years of combined clinical trial experience